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1086-155 Ventilatory Response to Exercise Improves Risk 
Stratif ication in Chronic Heart Failure Patients With 
Intermediate Functional Capacity 
Uao Corra. Alessandro Mezzani, Enzo Bosimini, Alessandro Imparato, Francasco 
Scapellato, Pantaleo Giannuzzi, S.Maugeri Foundation, Veruno, /ta/y. 
Background: Peak oxygen consumption (pVO2) has a reJevant prognostic rote in chronic 
heart failure (CHF), but its discriminatory power is limited in patients (pts) with intermedi- 
ate exercise capacity (pVO2 between 10-18 ml/kg/min.), thus, supplementary exertional 
indexes are most needed. Methods: Six hundred CHF pts with left ventricular ejection 
fraction (LVEF) <=40% who performed a symptom-limited cardiopulmonary exercise test- 
ing were followed up for 780±450 days. Results: Eighty-seven pts had major cardiac 
events (77 cardiac deaths and 10 urgent heart transplantations). Multivariate analysis 
revealed the rate of increase of minute ventilation per unit of increase of carbon dioxide 
production (VE/VCO2 slope) (chi2, 79.3, p<0.0001), LVEF (chi2, 24.6, p<0.0001) and 
pVO2 (chi2, 9,4, p<0.0001), as independent and additional predictors of major cardiac 
events. Cardiac events were significantly different in pts with pVO2 lower or equal to10 
ml/kg/min, compared to those with pVO2 greater or equal to 18 ml/kg/min.(37% vs 2% 
p<0.0001), whereas no difference was found among 403 pts with intermediate xercise 
capacity (17% in those with pVO2 greater than 10 to lower or equal to 14 ml/kg/min vs 
11% in those with pVO2 greater than 14 to lower than 18 ml/kg/min). In this cohort, VE/ 
CO2 slope resulted the strongest independent predictor of major cardiac events (chi2, 
20.9, p=0.0001) at multivariate analysis adjusted for NYHA functional class, LVEF, peak 
systolic blood pressure, percentage of predicted VO2, VO2 at ventilatory anaerobic 
threshold (VAT), and detectable VAT. The best cut off value for VE/VCO2 slope was 35 
(chi2, 25.8; RR= 3.2, 95% CI 2.0-5.1, p<0.0001): total mortality rate was 10% in pts with 
VFJVCO2 slope lower than 35 (n= 300: 74%) and 30% in those with VE/VCO2 slope 
greater or equal to 35 (n=103: 26%) (p<0.0001) and these pts showed comparable total 
mortality rate than those with pVO2 lower or equal to 10 ml/kg/min. (30% vs 37%: NS). 
Conclusions. A rational and pragmatic risk stratification process should involve both 
pVO2 and VE/VCO2 slope, distinctively, in patients with intermediate xercise capacity, 
as it offers an efficient predictive contribution for almost one fourth of them. 
1086-156 The Effect of Angiotensin-Converting Enzyme Inhibitor 
on Exercise Tolerance Time in Patients With Left 
Ventricular Dysfunction 
Jawdat Abdulla, Christian Torp-Pedersen, Steen Z. Abilstre m, Lars Kober, Department of 
Cardiology P, Gentofte University Hospital, Copenhagen, Denmark. 
Background: Despite controversy, the predominant concept states that angiotensin- 
converting enzyme (ACE) inhibitors improve exercise tolerance in patients with congas- 
tive heart failure. This study was therefore performed to evaluate whether an ACE inhibi- 
tor (trandolapril) prolongs exercise tolerance time in patients with left ventdcular 
dysfunction after myocardial infarction. 
Methods: In a prospective sub-study within Trandolapril Cardiac Evaluation study 
(TRACE), 305 patients (150 on placebo and 155 on trandolapril) with left ventdcular dys- 
function after myocardial infarction, were enrolled into a series of bicycle ergometry exer- 
cise tests at 1,3, and 12 months. Exercise time was measured in every test. 
Results: The two treatment groups were well matched at the baseline. The majority of 
the patients were in NYHA classes II and I. Exercise tolerance time increased in both pla- 
cabo and trandolapril groups from 6.3_+3.6 versus 8.7+3.5 minutes respectively at base- 
line to 9.0_+3.7 versus 9.1+3.6 minutes respectively after three months, and to 9.7_+3.8 
versus 9.8_+3.5 minutes respectively after 12 months. These changes were insignificant 
when compared the two treatment groups (P-values > 0.05). 
Conclusions: Traodolapdl does not improve exercise tolerance time in patients with left 
ventricular dysfunction after myocardial infarction. In contrast to the current concept, the 
TRACE study failed to confirm that ACE inhibitors have any effect on exercise tolerance. 
1086-157 Lean Tissue-Adjusted Versus Body Weight-Adjusted 
Peak Oxygen Consumption and Mortality Prediction in 
Chronic Heart Failure 
Madantonietta Cicoira, Costantinos Davos, Wolfram Doehner, Lorenzo Franceschini, 
Luise Zanolla, Andrew J. Coats, Piero Zardini, Stefan D. Anker, Divisione Clinicizzata di 
Cardiologia, Verona, Italy, Cardiac Medicine, London, United Kingdom. 
Background: peak oxygen consumption (peak VO2) is an important prognostic marker 
in chronic heart failure (CHF) patients. Peak VO 2 reflects oxygen extraction from the met- 
abolically active tissues (i.e,, the skeletal muscles); nevertheless, peak VO 2 is expressed 
in mL/min/kg of body weight (peak VO2-weight ). We assessed, whether the adjustment 
of peak VO 2 for lean tissue (peak VO2-1ean ) might provide better prognostic information 
than peak VO2-weight in CHF patients. Methods: Prospectively, 272 CHF outpatients in 
stable clinical conditions (mean age 61±12 years, NYHA class 2.3¢0.8) underwent a 
symptom-limited cardiopulmonary exercise testing, and evaluation of body composition 
with dual-energy X-ray absorptiometry. Results: Peak VO2-weight averaged 17.6¢5,7 
mtJkg/min and peak VO2-1ean 25.6¢8.1 mL//kg/min. During follow-up (mean 878±777 
days), 60 patients died (12-month survival: 89% [95% CI 85-g3]). Cox proportional haz- 
ard analyses showed that peak VO2-weight and peak VO2.1ean predicted survival (both 
p<0.0001), but at the log-likelihood ratio test peak VO2-1ean was significantly stronger 
than peak VO2-weight in predicting survival (p=0,002). The receiver operating character- 
istic area under the curve for peak VO2-1ean was significantly greater than for peak VO 2- 
weight at 12 , 15, 18 and 21 months follow-up (all p<0,03). In patients with mild CHF, 
peak VO2-1ean significantly predicted outcome (p=0.03), while peak VO2-weight lost its 
prognostic power. Conclusion: Adjustment of peak VO 2 for lean tissue instead for body 
weight provides a stronger prognostic parameter. This correction might be particularly 
useful in mild CHF and in subgroups of patients, such as in women and obese patients, 
in whom the prognostic value of peak VO 2 is less obvious. 
JACC March 6, 2002 
1086-158 Differential Effects of Carvedilol end Metoprolol  on 
Sympathetic Regulation of Peripheral Vascular 
Resistance In Patients With Chronic Heart Failure 
Katarzvna Hrvniewicz. Ana S. Androne, Alhakam Hudaihed, Stuart D. Katz, Columbia 
University College of Physicians & Surgeons, New York, New York. 
Increased vascular resistance in the skeletal muscle circulation of patients with chronic 
heart failure (CHF) is partly due to activation of the sympathetic nervous system. While 
the beneficial myocardial effects of inhibition of the sympathetic nervous system with 
beta-blockade have been previously studied, the effects of pharmacologically distinct 
beta-blockers on adrenergic regulation of vasomotor tone in patients with CHF are 
unknown. Accordingly, the current study was undertaken to assess the effect of chronic 
beta-blocker therapy on peripheral vascular responses to cold pressor test in patients 
with CHE We hypothesized that the peripheral vascular effects of carvedilol, an alpha- 
and non-selective beta-adrenergic receptor antagonist, and metoprolol, a selective beta- 
adrenergic receptor antagonist would differ.METHODS: Forearm vascular responses to 
cold pressor test (CPT)(immemion of hand and wrist in ice water for 2 minutes) was 
determined with strain gauge venous occlusion plethysmography in 26 patients with 
Class I-III CHF (mean age 55 years, mean EF 27%), treated with ACE-I, digoxin and 
diuretics. Forearm blood flow (FBF mVmin/100ml) was determined at 15s intervals during 
supine rest, during CPT and after 5 minutes of arterial occlusion. Mean arterial pressure 
(MAP, mmHg) was determined in the contrelateral arm with an automated cuff method. 
Forearm vascular resistance (FVR) was calculated in arbitrary units as the ratio of MAP 
and FBF. FVR was measured before and after 6 months of randomized assignment o 
carvedilol (25 mg bid, n=15) or metoprolol (ToprolXL 200 mg/day, n=10). RESULTS: In 
patients treated with carvedilol, FVR during CPT increased by 32.5% at baseline and by 
27.5% after 6 months. In patients treated with metoprolol, FVR during CPT before and 
after 6 months did not change (20.2% vs 20.9%). Minimal vascular resistance after 5 
minutes of transient ischemia decreased in patients treated with carvedilol (2.23 vs 2.04) 
and increased in patients treated with metoprolol (2.17 vs 2.45). CONCLUSIONS: During 
chronic therapy, mixed alpha/beta-adrenergic receptor blockade with carvedilol reduces 
forearm vascular resistance to a greater extent than metoprolol. 
1086-159 Does a Combined Treatment With Vitamin E and 
Atorvastatin Improve Endothelial Function and Ejection 
Fraction in Patients With Heart Failure? A Double Blind 
Placebo Controlled Study 
Dimitris Tousoulis. Charalambos Antoniades, Stella BrilU, Costas Tentolouris, Kydakoula 
Marinou, Athanasios Trikas, Ioannis Barbetseas, Chdstos Pitsavos, Christodoulos 
Stefanadis, Pavlos Toutouzas, Cardiology Unit, Hippokration Hospital, Athens University 
Medical School, Athens, Greece. 
Background: Previous studies have shown that endothelial function is compromised in 
heart failure and coronary artery disease. Treatment with statins or antioxidant vitamins 
improves endothelial function in patients with atheroscleresis. In this study we assessed 
the effect of atorvastatin alone or in combination with vitamin E on endothelial function 
and ejection fraction in patients with heart failure. 
Methods: In this double blind placebo controlled study, 47 patients with heart failure (30 
males, 17 females) were enrolled. 16 patients received 10mg atorvastatin/day (group A), 
13 patients received atorvastatin 10 mg]day plus vitamin E 4001U/day (group B) and 18 
other patients received placebo (group C) for 4 weeks. All patients were NYHA II to IV, 
having an ejection fraction < 40%. Forearm blood flow was measured using venous 
occlusion strain-gauge plethysmography. Endothelium dependent flow mediated vasodi- 
lation (FMD) was expressed as the % change from baseline to maximal flow during reac- 
tive hyperemia. Endothelium independent flow (NTR%) was assessed as the % change 
from baseline to post subtingual nitroglycerin administration flow. Ejection fraction of the 
left ventricle was estimated with Simpsons method. 
Results. Blood pressure, heart rate, basel forearm blood flow, NTR% and body weight 
were similar before and after the treatment in these three groups. FMD was significantly 
increased in groups A and B (from 45.14+/-5.4% and 49.0+/-4.3% to 93.04+/-13% and 
73.7+/-5.1% respectively, p<0.01 for both) while no significant change was observed in 
group C. The improvement of FMD was not different between groups A and B. Ejection 
fraction was also improved in groups A and B (from 26.1+/-0.91% and 23.1+/-0.9% to 
28.92+/-1.1% and 27.1+/-1.1% respectively, p<0.05 for both), while remained unaffected 
in group C (from 25.9+/-0.88% to 26.7+/-1.0%, p=NS). 
Conclusions: These findings indicate that atorvastatin treatment for 4 weeks significantly 
improves endothelial function and ejection fraction in patients with ischemic heart failure. 
Combined administration of atorvastatin and vitamin E does not offer any further 
improvement of these two parameters. 
1086-160 Coronary Endothelial Dysfunction Occurs Early in the 
Pathophysiology of Heart Failure 
Abhiram Prased. Jassim AI Suwaidi, Stuart 1". Higano, Geralyn M. Pumper, David R. 
Holmes, Ryan Lennon, Amir Lerman, Mayo Clinic, Rochester, Minnesota. 
Background; Though coronary endothelial dysfunction is associated with heart failure, 
relatively little is known regarding their temporal relationship. We hypothesized that 
endothelial dysfunction is an early feature of systolic left ventricular dysfunction. The pur- 
pose of this study was to evaluate whether coronary endothelial dysfunction is present in 
patients with aymptomatic left ventricular dysfunction. 
Methoda: 371 consecutive patients with normal or mild coronary atherosclerosis at 
angiography underwent assessment of coronary endothelium-dependent vasomotion 
using intracoronary acetylcholine (ACH), and coronary flow reserve (CFR) was mea- 
sured with intracoronary adenosine. Coronary blood flow (CBF) was derived from mea- 
surements of epioardial diameter lED) and blood velocity using quantitative angiography 
and Doppler guidewire, respectively. Patients were divided into two groups: left ventricu- 
